


Ocular tissue regeneration with serum and platelet rich plasma









COL® system with PRP or serum: a unique solution in Ophthalmology


Biomed Device helps improve patient care with its innovative products and intelligent solutions for the preparation and preservation of eye drops with blood components, such as serum and platelet rich plasma (PRP).

The COL® System for Ophthalmology has been specifically designed by Biomed Device to offer a complete and simple to use system for ocular pathologies and trauma.

Biomed Device 's clinical know-how permits us to reach excellence in the preparation, delivery and preservation of blood components, and to continually progress towards new and groundbreaking advances.







Ocular chronic diseases

COL® is used for the administration of serum eye drops with chemical, trophic and physical characteristics similar to human tears. This natural tears substitute is used in treatment of chronic and dry-eye related ocular disorders.

Ocular tissue damage and disorders

Growth factors found in PRP permit accelerated tissue regeneration, by using a small amount of patient's own blood. Biomed Device, with its COL® product line, offers an innovative and unique solution during reconstruction, remodeling and treatment of the ocular surface.



Rationale of use

EYE DROPS WITH SERUM

Human tears are rich in "natural unique elements" and growth factors, such as vitamins, fibronectin, cytokines, albumin, important for maintaining a healthy corneal and conjunctival epithelium. These components cannot be found in **artificial tear preparations** which often contain preservatives, stabilizers and other additives, which potentially induce allergic reactions. **Eye drops from autologous serum** resolve these drawbacks with their tear-like biochemical characteristics and supply nutritional components (Table I). Therefore it is used "not only to humidify the eye surface, but also to provide nutritional and growth factors necessary to maintain cellular feasibility in the epithelial repair processes, and bactericide components which reduce the risk of contamination and infection".*¹

COMPARATIVE CONCENTRATIONS OF TEARS AND AUTOLOGOUS SERUM OF THE MAIN EPITHELIOTROPHIC FACTORS

	EGF (ng/ml) epithelial growth factor	TGF-B (ng/ml) transforming growth factor	VITAMIN A (mg/ml)	LYSOZYME (mg/ml)	FIBRONECTIN (µg/ml)
TEARS	0.2 - 3.0	2 - 10	0.02	1 - 4	21
SERUM	0.5	6 - 33	46	6	205

^{*1} López-García J. S., García-Lozano I., Rivas L., Martínez-Garchitorena J., Use of autologous serum in ophthalmic practice, Arch Soc Esp Oftalmol 2007; 82: 9-20.


EYE DROPS WITH PRP: PHYSIOLOGICAL PROCESS


Platelets provide a variable pattern of biomolecules actively participating in each phase of tissue repair.

The process starts from an initial phase of propagation of the inflammatory process to the next phase of cell recall and finally to the release of growth factors (GF). These then trigger mechanisms such as proliferation, differentiation and angiogenesis, leading to wound healing (Fig. 1). PRP regenerating effect is largely related to the presence of growth factors: DGF (Platelet Derived Growth Factor); TGF (Transforming Growth Factor); VEGF (Vascular endothelial growth factor); EGF (Epidermal Growth Factor); FGF (Fibroblast Growth Factor); IGF (Insulin - like Growth Factor).

PRP acts on **infiammation and tissue regeneration** during the healing process (Fig. 2).

Wound healing time is reduced, with the consequent **reduction of pain** and **an improvement of recovery** (Fig. 3).





WITH PRP HAEMOSTASIS INFLAMMATION TISSUE REGENERATION TISSUE REMODELLING
WITHOUT PRP HAEMOSTASIS INFLAMMATION TISSUE REGENERATION TISSUE REMODELLING


COL® is a closed and sterile certified system for serum and PRP eye drops

The most important applications for use of eye drops obtained with COL® include the following:

- Corneal lesions and dystrophy
- Neurotrophic keratopathy
- Superficial punctuate keratitis
- Keratopathy with loss of epithelial stromal tissue resulting from chemical or physical traumas
- Sicca Syndrome or Sjögren's Syndrome
- Severe dry eye-related ocular surface disorders
- Ocular GvHD
- Recurrent erosion syndrome


COL® system is the first dedicated, certified, closed and sterile circuit for the collection, conservation and application of autologous blood components for ophthalmic use.

All the COL® line products are covered by international industrial patents.




Preparation of autologous blood components with Eye Drops Bags and COL®

SERUM EYE DROPS: FOR EXTENDED USE IN CHRONIC DISEASES



EYE DROPS WITH PRP FOR OCULAR TISSUE REGENERATION



The entire process of PRP preparation should be carried out in a clean and sterile place with aseptic technique.

Biomed System range of products

- PRP BASIC PREPARATION KIT SYSTEMS
- PRP CENTRIFUGE AND LAB EQUIPMENT
- COL® OPHTHALMOLOGY LINE
- EYE DROP BAGS FOR SERUM PREPARATION

REFERENCES:

- [Autologous serum in treatment of dry eye] Review · Babic G. S., Cekic S. · Med Pregl. 2012 Nov-Dec; 65 (11-12): 511-15 · Serbian
- Allogeneic serum eye drops for the treatment of dry eye patients with chronic graft-versus-host disease · Na KS, Kim MS · J Ocul Pharmacol Ther. 2012 Oct; 28 (5): 479-83 · Epub 2012 Jun 25
- Autologous platelet lysate for treatment of refractory ocular GVHD · Pezzotta S., Del Fante C., Scudeller L., Cervio M., Antoniazzi E. R., Perotti C. · Bone Marrow Transplant. 2012 Dec; 47 (12): 1558-63 · DOI: 10.1038/bmt. 2012.64 · Epub 2012 Apr 23
- Blood components for topical use in tissue regeneration: evaluation of corneal lesions treated with platelet lysate and considerations on repair mechanisms · Vecchio S., W. Geremicca , C. Fonte · Blood Transfus 2010; 8: 107-12 · DOI: 10.2450/2009.0091-09
- Comparison of autologous serum eye drops with different diluents. · Cho YK, Huang W, Kim GY, Lim BS · Curr Eye Res. 2013 Jan; 38(1): 9-17 · DOI: 10.3109/02713683.2012.720340 · Epub 2012 Aug 28
- Effect of autologous platelet-rich plasma on persistent corneal epithelial defect after infectious keratitis · Kim KM, Shin YT, Kim HK · Jpn J Ophthalmol. 2012 Nov; 56(6):544-50 · DOI: 10.1007/s10384-012-0175-y · Epub 2012 Sep 13
- The role of "eye platelet rich plasma" (E-PRP) for wound healing in ophthalmology · Alio J. L., Arnalich Montiel F., Rodriguez A. E. · Curr Pharm Biotechnol. 2012 Jun; 13(7):1257-65
- The use of platelet-rich plasma for the topical treatment of corneal lesions · Vecchio S., E. Santilli, A. R. D. Ettoris, V. Musuraca, P. Leonardo, P. Maltese, W. Geremicca, G. Schipani · Blood Transfus 2006; 4: 133-40
- Topical autologous platelet-rich plasma eyedrops for acute corneal chemical injury · Panda A., Jain M., Vanathi M., Velpandian T., Khokhar S., Dada T. · Cornea. 2012 Sep; 31 (9):989-93 · DOI: 10.1097/ICO.0b013e3182114661
- Use of autologous serum in the treatment of ocular surface disorders · Jeng BH. · Arch Ophthalmol. 2011 Dec; 129(12): 1610-2 · DOI: 10.1001/archophthalmol. 2011.336



BIOMED DEVICE S.R.L. via Vittorio Bottego, 239 41126 Modena - Italy

tel. +39.059.343929 fax +39.059.4550010 e.mail info@biomeddevice.it www.biomeddevice.it All products are **C C** certified in accordance with European Directives.

Biomed Device is a certified company:





UNI EN ISO 9001:2008 UNI EN ISO 13485:2012

Biomed Device products are medical devices and not available to the general public, and must be used only by authorized personnel. Biomed Device reserves the right to change the products at any time, in line with technical innovation and product improvement. This informative material is for the exclusive use of authorized personnel.